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static. Current U.S. Food and Drug Administration (FDA)-approved anabolic drug treatments therapeutically aimed at stimulating bone growth include recombinant human bone morphogenetic protein (rhBMP)-2, rhBMP-7, and teriparatide (a recombinant fragment of the parathyroid hormone [PTH] 1-34) 2 . Of these drug treatments, only rhBMP-2 is indicated for fracture management and is limited to open tibial shaft fractures. The use of these treatments has not gained consensus indication in fracture management because of limitations with respect to required local implantation, systemic injection, and/ or high costs. An inexpensive and noninvasive approach to augment fracture repair could decrease the overall time to healing and reduce the occurrence of delayed union.
Lithium, a glycogen synthase kinase (GSK)-3b inhibitor, has a positive impact on bone formation in patients with bipolar disorder who are receiving therapeutic doses of lithium [6] [7] [8] . Although GSK-3b proteins are one of many targets for lithium, its action to inhibit GSK-3b, activating the canonical Wingless (Wnt)/b-catenin signaling pathway, is important in bone biology and as a mechanism of increasing bone formation 2, 9, 10 . Lithium's potential to induce bone growth may have a direct clinical implication for treating fractures. Mesenchymal progenitor cell recruitment occurs during the inflammatory phase of fracture repair. As Wnt signaling is activated during the proliferative phase, mesenchymal progenitor cells are induced to differentiate into osteogenic progenitors for mineralization and bone development. In concert with this process, lithium's anabolic effects seem to be effective when given after a fracture has occurred 11 , during Wnt-signaling activation. This concept is particularly advantageous for clinical applications, since patients who sustain a fracture are referred to an orthopaedic surgeon during the early inflammatory and proliferative phases of fracture-healing, which typically occur in the first two weeks after injury.
Prior to consideration of lithium for clinical use, further studies are needed to delineate the precise administration parameters specifically for fracture care. As a psychoactive medication, lithium interacts with neuronal monovalent or divalent cation transport in the central nervous system. Psychopharmacological dosing guidelines for bipolar disorder and mania can yield serum levels approaching toxic levels. Lithium side effects and toxicity generally become more evident and concerning at doses that yield serum levels above the recommended upper limit of 1.2 mEq/L 12 . Normally, clinical dosing begins at 300 mg/day, increasing to a maintenance serum level of 0.8 mEq/L (less for the elderly and children). The narrow therapeutic-to-toxic ratio of lithium necessitates monitoring for plasma concentrations in this patient population. However, for its effects on bone, we postulate that such monitoring may not be necessary, as the required lithium dose would be substantially lower. Currently, no studies to our knowledge have explored lithium-administration parameters (dose, treatment onset, and treatment duration) with respect to effects on bone regeneration and potential interactions during fracture repair. This is a void in our present knowledge of a known Wnt pathway modulator that is important in bone formation and is safe, accessible, and cost effective. The objective of this preclinical study was to determine the influence of lithium-administration parameters on the quality of the healing of long bones. Our hypothesis was that lithium dosage would be the most critical parameter affecting fracture repair, followed by duration and onset of treatment after fracture.
Materials and Methods

Experimental Design
A dministration parameters of dose, treatment onset, and treatment duration were investigated with use of a three-factor design-of-experiments approach. Administration parameters were considered at combinations of high and low factor levels, yielding eight experimental groups (Fig. 1) . A ninth experimental group was included with all parameters set at middle factor levels (to account for potential nonlinear responses) along with two external control groups (no treatment and sham treatment with saline solution).
Animal Model
Eighty-four healthy twelve-week old female Sprague Dawley rats (weight, approximately 300 g) were subjected to a closed midshaft unilateral femoral fracture generated with the technique of Bonnarens and Einhorn 13 , slightly modified by prestabilizing the pin through engaging the proximal cortex and cutting the pin flush distally. The fracture was allowed to heal over twenty-eight days while lithium was administered via daily oral gavage with the rats under light anesthetic 14 . All animals were euthanized at twenty-eight days after fracture, the femora were harvested bilaterally, and the intramedullary pins were removed ( Fig. 2) . Biomechanical testing, microcomputed tomography (mCT)-based three-dimensional bone stereology, and torsional rigidity analysis were used to evaluate how variations in lithium treatment affected the overall quality of bone-healing.
Stereological Analysis
Following harvest, each rat femur was imaged at an isotropic voxel size of 14.8 mm (55 kV, 200 mA, beam-hardening correction factor of 1200 mg hydroxyapatite [HA]/cm 3 ; mCT 100 scanner; Scanco Medical, Brüttisellen, Switzerland). The intensity-bone density relationship was generated via scanner precalibration with use of HA phantoms. Reconstructed scans were exported as Digital Imaging and Communications in Medicine images (DICOMs) into Amira software (version 5.4; Visage Imaging, Carlsbad, California) to crop and align the region of interest. The region of interest was denoted as a fixed distance from the midway point of the lesser trochanter proximally to the start of the patellar notch distally (Fig. 3) . A fixed global threshold of 25% of the maximum native grayscale value, corresponding to a mineral density of 365 mg HA/cm 3 , was used to differentiate mineralized tissue that was included in the analysis from excluded unmineralized or poorly mineralized tissue 15 . A custom processing module was then used for stereological analysis (CT analyzer software; SkyScan, Kontich, Belgium). Consistent with the results of other papers that have investigated fracture-healing in a rodent closed femoral fracture model [15] [16] [17] , stereological parameters-including bone volume, total volume, bone volume fraction, bone mineral density, tissue mineral density, and bone mineral content-were calculated. Minimum and average computed tomography (CT)-based torsional rigidity were also calculated with the method developed by Nazarian and colleagues 18 .
Biomechanics
Destructive torsional testing was used to determine the mechanical properties of the healing long bones 19 . Each femur was aligned longitudinally to the loading Diagram showing the high, middle, and low factor levels for lithium dosing, treatment-onset, and treatment-duration parameters explored in this study. In the screening phase, eight experimental groups were tested at the eight different combinations of high and low factor levels. A ninth group was tested at middle factor levels, while two control groups (receiving no treatment or sham treatment with saline solution) were tested outside the cubic design space.
axis of a Bionix 858 materials testing system (MTS Systems, Eden Prairie, Minnesota), with its proximal and distal ends potted in bone cement (polymethylmethacrylate) at a constant gauge length of 15 mm 20, 21 . A 1.4-N-m reaction torque transducer (Futek, Irvine, California) measured applied torque. An angular displacement of 1.5°/sec was applied until failure occurred or until a maximum angular displacement of 50°was achieved 22, 23 . Maximum yield torque, twist angle at failure, and experimental torsional stiffness were determined on the basis of the generated load displacement curves. Maximum yield torque was used as the primary study outcome measure to assess the quality of fracture repair.
Design-of-Experiments Modeling and Data Analysis
Eleven different outcome responses were obtained (maximum yield torque, twist angle at failure, experimental torsional stiffness, bone volume, total volume, bone volume fraction, bone mineral density, tissue mineral density, bone mineral content, minimum torsional rigidity, and average torsional rigidity). Data were reported as the mean and standard deviation. Design-of-experiments system modeling was conducted on the primary outcome measure (maximum yield torque) and the ten secondary outcome responses with use of a commercial design-of-experiments-specific statistical package (Design-Ease 7; StatEase, Minneapolis, Minnesota). Raw data were imported into the software in coded matrix notation, and data normality was confirmed. When the data deviated from normality, an appropriate Box-Cox transformation was applied to the output responses to help stabilize the variance. A sum-of-squares chart was used to determine which terms were included in the model space based on a 10% weighted contribution threshold for inclusion. Analysis of variance (ANOVA) was used to determine whether the model itself was significant, which effects and interactions were significant to the model, and whether the model showed significant curvature, indicating a nonlinear or saturated response within the cubic design space. In all cases, a p value of <0.05 was considered significant. To account for the use of multiple and independent estimates made from the same data, a Bonferroni correction 24 was applied: the alpha level was divided by the number of estimates. Comparisons of selected treatment groups were conducted with respect to the experimental control groups outside the design-of-experiments space. Additional comparisons were made between these select treatment groups and the experimental controls on the contralateral, nonfractured femora in order to investigate lithium's potential effect on the off-target limb.
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Results
I
n our study, exclusion criteria for an unacceptable fracture based on radiographs made immediately after fracture were extramedullary malpositioning of the pin, a nondiaphyseal fracture, and a complex unstable fracture with substantial femoral shortening that was not amenable to immediate weight-bearing on the affected limb. Rats with open fractures and postoperative wound infections were also excluded. Of the eighty-four animals that underwent surgery, fourteen were excluded for the following reasons: wound infection (two), extramedullary pin placement (five), nondiaphyseal fractures (three), and unstable and/or complex fractures (four).
Significantly Positive for Bone-Healing: Later Onset of Treatment The design-of-experiments analysis found only four response models to be statistically significant (maximum yield torque, tissue mineral density, minimum torsional rigidity, and average torsional rigidity). A summary of the biomechanical and stereological data on these four responses is provided (Table I) along with the results from the design-of-experiments models (see Appendix). In each model, treatment onset was the only Illustration showing the region of interest used in the stereological analysis.
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significant input parameter. In the maximum yield torque (p = 0.0125) and both torsional rigidity models (p = 0.0035 and p = 0.0114), increasing the time to treatment onset was significantly positive for the response, whereas in the tissue mineral density model (p = 0.005), increasing the time to treatment onset was significantly negative for the response. In three other secondary models (experimental torsional stiffness, bone volume, and total volume), treatment onset was the input parameter with the largest (albeit nonsignificant) effect on the output response. In the maximum yield torque response, defined as the primary study outcome measure used to quantify the quality of bone-healing, ANOVA showed that the model was significant (p = 0.02) and that onset of treatment was the only significant term in the model space, with later onset (seven days after fracture) showing a 21% increase in maximum yield torque compared with those treated at an earlier onset (three days after fracture) (p = 0.01).
Positive for Bone-Healing: Lower Dose and Longer Treatment Duration
The next largest contributions to the model space were dose (effect = 21.70, 22% contribution; p = 0.11) and treatment duration (effect = 1.57, 18% contribution; p = 0.14). The direction of each input effect indicated that increasing time to treatment onset and increasing treatment duration had a positive influence on the maximum yield torque output response (positive effect), whereas increasing dose negatively influenced this outcome (negative effect). No interaction effect exceeded the 10% weighted threshold and, thus, all interaction terms were applied as model error (Fig. 4) . In addition, the model had no significant curvature (p = 0.77), implying that the output responses displayed linear behavior, with no indication of saturation within the cubic design space.
Optimal Parameters for Dose, Treatment Onset, and Treatment Duration Collectively, the design-of-experiments analysis suggested that the best treatment combination occurred when input factors were set to lower dose (twenty milligrams per kilogram of body weight per day), later treatment onset (seven days after fracture), and longer treatment duration (two weeks) (Group 10, low/high/high). The worst treatment combination occurred when input factors were set to the opposite extremes: a higher dose (100 milligrams per kilogram of body weight per day), earlier treatment onset (three days after fracture), and shorter treatment duration (one week) (Group 5, high/low/ low) (Fig. 5) . Representative three-dimensional models of and C are labeled, as these are the most important factors. Treatment onset showed the largest effect, followed by dose and then treatment duration. The tip of the onset bar extends beyond the t-value limit of 2.00856, implying that this effect was significant to the model space.
Orange bars depict positive effects, whereas blue bars represent negative effects. 
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healing femoral fractures from Groups 10 and 5 are shown in Figure 6 . The treatment combination of lower dose, later onset, and longer duration maximized the primary outcome response of maximum yield torque, demonstrating a significant (46%) increase over pooled controls (481.1 ± 104.0 N-mm compared with 329.9 ± 135.8 N-mm; p = 0.04). The opposite combination of treatment parameters (higher dose, earlier onset, and shorter duration) demonstrated a 22% reduction in maximum yield torque compared with pooled controls; however, this was not significant (255.8 ± 89.1 N-mm compared with 329.9 ± 135.8 N-mm; p = 0.246). There were no significant differences between the group of untreated controls and the group receiving sham treatment with oral administration of saline solution (p ‡ 0.05). Thus, multiple sedations for oral gavage had no effect. No significant differences were observed in the contralateral limbs between these groups in any mechanical or stereological outcome parameters, except for a small increase in tissue mineral density in comparing Group 10 with Group 5 (3.1%; p = 0.03; see Appendix).
Discussion
T he canonical Wnt/b-catenin pathway has emerged as a promising therapeutic target to modulate bone growth 2 . This pathway influences the osteoblast lineage, stimulating mesenchymal progenitor precursors to differentiate into mature osteoblasts 25, 26 . In the early stages of fracture repair, b-catenin is needed to direct mesenchymal precursors into their respective chondrocyte and osteoblast lineages. Once mesenchymal precursors have committed to the osteoblast lineage, increasing Figs. 6-A, 6-B, and 6-C Three-dimensional isosurface models and microcomputed tomography image slices of three rat femora used in the study at twentyeight days after fracture. Fig. 6 -A depicts a healing femur from a rat that was in experimental Group 10, which received the combination of lithium treatment that was determined to be the best (lower dose, later treatment onset, and longer treatment duration). Fig. 6 -B depicts a healing femur from a rat that was in experimental Group 5, which received the combination of lithium treatment that was determined to be the worst (higher dose, earlier treatment onset, and shorter treatment duration). Fig. 6 -C depicts an intact contralateral femur from a control rat that was in experimental Group 6.
b-catenin levels improve osteogenesis 26 . Thus, to positively influence fracture-healing, stimulation of Wnt/b-catenin signaling must occur after mesenchymal precursors have been committed to the osteoblast lineage. Therapeutic strategies aimed to enhance Wnt/b-catenin pathway activity during this critical period have tremendous potential as anabolic interventions for bone growth and possible new treatments for fracture repair. Lithium has various mechanisms of action, many of which are interconnected and relate back to Wnt/b-catenin activation via downstream GSK-3b inhibition 27, 28 (Fig. 7) . Lower doses of lithium could result in signal amplification or, conversely, higher doses could saturate signaling to interfere with proper bone-healing 28 . Clearly, proper regulation of GSK-3b is imperative 29 . The administration of lithium stimulated bone growth during fracture-healing. Our results suggest that a combination of a lower dose (twenty milligrams per kilogram of body weight per day), later treatment onset (seven days after fracture), and longer treatment duration (two weeks) improved bone-healing, with a significant (46%) increase in maximum yield torque over pooled controls. The timing of treatment onset was the most influential parameter, suggesting that the exact timing of administration is the most crucial factor in optimizing the treatment regimen. Delayed administration with use of other anabolic treatments, such as BMP-2, at five and ten days postoperatively for critical-sized femoral bone defects has also demonstrated enhanced mineralization and greater mechanical strength in rabbit and rat models 30 . These findings align with our knowledge of bone-healing as a highly coordinated and tightly regulated temporal physiological process. Our results suggest that short-term systemic lithium treatment successfully targets the healing femoral fracture and does not influence the mechanical properties or microstructure of the intact contralateral limbs.
The ideal therapeutic influence of lithium must target the timing when mesenchymal precursors become committed to the osteoblast lineage 11 , a cellular transition closely linked to the physiological shift from soft to hard callus during endochondral fracture repair. While the exact timing is not conclusive, evidence suggests that this soft-to-hard callus transition peaks between seven and fifteen days after fracture in the rodent [31] [32] [33] . Therefore, lithium therapy aimed at enhancing fracture-healing should target this time range to be most effective. Typically, the rate of union for simple fractures in Sprague Dawley rats is four to six weeks 34 compared with healing in adult humans, which is usually six weeks or more. In our study, we chose a treatment onset of seven days after fracture as our high factor boundary to target the beginning of this physiologic transition. Our results demonstrate a nonsignificant curvature in treatment onset, implying that the outputs displayed an increasing linear trend with no indication of saturation within the factor range tested. As such, the optimal timing for the onset of treatment may lie outside the current design space tested. Further work targeting a treatment onset between seven and fifteen days after fracture (the range for primary callus turnover) is needed to determine whether further delaying treatment onset would benefit the mechanical properties of the healing fracture.
No benefit of higher lithium dose was found. Contrary to expectations, the lower dose of lithium showed a trend toward superior fracture-healing (twenty compared with 100 milligrams per kilogram of body weight per day, maximum yield torque increase of 19%; p = 0.11). Clinically, this finding is very encouraging, as it suggests that patients could benefit from taking very low dose lithium to maximize its positive influence on fracture-healing and substantially reduce its potential adverse systemic effects, as lithium toxicity is dose dependent. Lithium's major side effects are primarily acute, occurring when levels exceed recommended therapeutic levels. The lower dose of lithium used in our study is nearly four times lower than the regular maintenance dose for lithium's psychotropic indication in the treatment of bipolar disorder 35 , which may suggest that the lithium levels needed to improve bone-healing come with minimal risk of acute toxicity. Furthermore, while there are clinically major long-term concerns-including hyperparathyroidism, hypothyroidism, and nephrogenic diabetes insipidus-in patients managed with lithium [36] [37] [38] , these long-term side effects may be less relevant in short-term lithium use for bone-healing.
Duration of lithium treatment was the least influential treatment parameter, with a nonsignificant trend toward a longer duration showing improved bone-healing. With two weeks of lithium treatment, the period of endochondral ossification in the rat approached completion, at which time mineralization predominated as the cartilage template diminished. This transition may mark the boundary of when lithium therapy may no longer be needed or even be effective. Consequently, the duration of treatment may be reduced if an even later onset of treatment (beyond seven days after fracture) is found to be equivalent or more beneficial.
A strength of this study is the application of the designof-experiments methodology. A one-factor-at-a-time approach is commonly utilized in preclinical study design, whereby each Lithium's mechanism of action as it relates to glycogen synthase kinase (GSK)-3b. Lithium has the ability to both directly and indirectly inhibit GSK-3b activity, making it an appealing therapeutic strategy to stimulate Wnt/b-catenin signaling. Direct inhibition occurs via competition with Mg 21 at the GSK-3b active site. Indirect inhibition occurs via serine 9 phosphorylation at the GSK-3b N-terminus. cAMP = cyclic adenosine monophosphate, PKA = protein kinase A, P = phosphorylation site, PI3K = phosphatidylinositol 3-kinase, PKB = protein kinase B, and PKC = protein kinase C.
factor is varied independently while all other factors remain fixed. One-factor-at-a-time approaches require a large number of samples to achieve adequate power to compare multiple variables, and they are unable to elucidate interactions that may occur among factors. More importantly, when multiple parameters are evaluated for the purpose of selecting a treatment protocol, one-factor-at-a-time designs may miss the individual combination that represents the optimal outcome. For example, it is possible that the optimal parameters of dose, treatment onset, and duration for lithium administration in fracturehealing will not be tested with use of this type of experimental method. Design of experiments is a statistically more powerful and efficient methodology for studying two or more parameters that may interact and have nonlinear effects. A wellestablished technique widely used in engineering analyses, it has been developed specifically with the intention of efficiently identifying the relative influences of factors and the combination of them producing an optimal response and reducing variability. Design of experiments has been successfully implemented in a few biological studies pertaining to microarray protocol optimization 39, 40 and assay parameter selection 41 . However, to our knowledge, there have been no documented studies in which the design-of-experiments approach has been used in an in vivo, preclinical, translational drug study focused on exploring optimized treatment regimens.
Overall, while later treatment onset was the only significant parameter shown to improve bone-healing, nonsignificant trends indicated that a lower dose and longer duration also had positive effects on the healing response. These findings are encouraging from a clinical perspective, as they support the administration of lithium to manage patients receiving orthopaedic care after a fracture has occurred.
Lithium therapy is emerging as a very promising option in bone repair, and the results of our study form a critical foundation for future translational studies. As this optimization study is limited by its use of a rodent model, appropriate large-animal proof-of-concept models, safety data, and FDA clinical trials approval are needed.
